The computational disease model developer CytoReason has announced that it has entered into a multi-year partnership with Pfizer (NYSE:PFE) that is potentially worth $110 million over the next five years.
In the recent partnership, Pfizer will make a $20 million equity investment in CytoReason. The company will also obtain options to license platform and disease models from Tel Aviv–based CytoReason.
The new collaboration will center around Pfizer’s focus on developing a variety of disease models and high-resolution models for several therapeutic areas.
The two companies began working together in 2019.
Pfizer has used CytoReason’s biological models of the immune system for drug development efforts related to immune-mediated and immuno-oncology diseases.
CytoReason reports that Pfizer has used its platform for R&D programs related to more than 20 diseases.
“CytoReason’s biological data allows us to gai…